Letrozolo Zentiva

Letrozole, the active ingredient in Letrozolo Zentiva, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of postmenopausal women with hormone receptor‑positive breast cancer, reducing estrogen‑driven tumor growth.

GNH USA supplies Letrozolo Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with a focus on reliable quality, regulatory compliance and timely delivery to meet the needs of cancer care providers across global markets through established distribution networks.

Letrozole is used as an endocrine therapy targeting estrogen‑dependent breast cancer pathways.

Postmenopausal hormone receptor‑positive breast cancer: reduces risk of disease recurrence and progression. Adjuvant therapy for early‑stage disease: improves disease‑free survival after surgery. Metastatic breast cancer: provides disease control in patients with advanced hormone‑sensitive tumors.

Letrozole may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Diarrhea

Serious or Rare Side Effects: - Osteoporosis or bone fracture - Severe liver injury (hepatitis, hepatic failure) - Pulmonary embolism or deep‑vein thrombosis - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Cardiovascular events (myocardial infarction, stroke)

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.

Monitor bone health: assess calcium, vitamin D status and consider bisphosphonates. Assess liver function: perform baseline and periodic liver enzyme tests. Evaluate cardiovascular risk: monitor lipid profile and blood pressure. Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. Counsel on pregnancy risk: contraindicated in pregnancy; effective contraception required. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Letrozole can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant estrogen replacement therapy: may negate therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce plasma levels and efficacy.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity. - Warfarin: potential increase in INR, monitor coagulation parameters. - Statins (e.g., simvastatin): may require dose adjustment due to shared metabolic pathways.